Product Information
CAPLYTA 21 MG CAPSULE is a brand product labeled by Intra-Cellular Therapies, Inc, priced at $57.2004 per EA under NDC 72060012140. Its NADAC has been published 202 times since Nov 23, 2022.
FDA first approved this application on Dec 20, 2019.
Strength
21 mg/1
Manufacturer
Intra-Cellular Therapies, IncNDC
72060012140
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LUMATEPERONEApproval Type
New Drug (NDA)
FDA Application
NDA209500FDA Approved
12/20/2019
On Market Since
8/9/2022
Pharmacological Classes
Price Statistics
The NADAC for CAPLYTA 21 MG CAPSULE has been published 202 times since Nov 23, 2022, and over the history we have for it it has risen 20.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $57.2004 per EA |
|---|---|
| All-time high | $57.3534 (May 13, 2026) |
| All-time low | $47.4243 (Nov 23, 2022) |
| 52-week high | $57.3534 |
| 52-week low | $54.5952 |
| Median price | $53.1493 |
| Average price | $53.3778 |
| Largest weekly change | +5.9% (Jan 4, 2023) |
| Weeks tracked | 202 |
| Tracking since | Nov 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lumateperone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Intra-Cellular Therapies, Inc manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lumateperone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CAPLYTA 21 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CAPLYTA 21 MG CAPSULE, manufactured by Intra-Cellular Therapies, Inc, is $57.2004 per EA (NDC 72060012140), effective Sep 30, 2026.
How has the price of CAPLYTA 21 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CAPLYTA 21 MG CAPSULE has risen 20.6%. It has been tracked across 202 weekly CMS publications since Nov 23, 2022.
What are the highest and lowest recorded NADAC prices for CAPLYTA 21 MG CAPSULE?
Since Nov 23, 2022, the NADAC for CAPLYTA 21 MG CAPSULE has ranged from a low of $47.4243 (Nov 23, 2022) to a high of $57.3534 (May 13, 2026), with a median of $53.1493 per EA.
Are there cheaper alternatives to CAPLYTA 21 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of CAPLYTA 21 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CAPLYTA 21 MG CAPSULE?
CAPLYTA 21 MG CAPSULE (NDC 72060012140) is labeled by Intra-Cellular Therapies, Inc, and CMS classifies it as a brand product.